Get the Stockscreener App
244.76
0.13%
0.32
After Hours:
244.76
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $244.76, with a volume of 305.19K.
It is up +0.13% in the last 24 hours and down -4.03% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$244.44
Open:
$244.29
24h Volume:
305.19K
Relative Volume:
0.29
Market Cap:
$35.73B
Revenue:
$5.26B
Net Income/Loss:
$1.44B
P/E Ratio:
25.05
EPS:
9.7713
Net Cash Flow:
$1.76B
1W Performance:
-0.07%
1M Performance:
-4.03%
6M Performance:
-4.47%
1Y Performance:
+4.65%
1-Day Range:
$243.50
$245.99
1-Week Range:
$243.07
$247.45
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
244.76 | 35.68B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
577.81 | 204.60B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
196.33 | 55.88B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.38 | 39.38B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.13 | 34.85B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. $RMD Stock Holdings Raised by Pacer Advisors Inc. - MarketBeat
Why analysts maintain buy rating on ResMed Inc. (RME) stockGlobal Market Influence & Big Gains Small Capital - bollywoodhelpline.com
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Voya Investment Management LLC Has $8.97 Million Position in ResMed Inc. $RMD - MarketBeat
Swedbank AB Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Is ResMed stock underperforming the S&P 500? - MSN
OLD National Bancorp IN Increases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Patton Fund Management Inc. Has $265,000 Stock Holdings in ResMed Inc. $RMD - MarketBeat
Confluence Investment Management LLC Sells 4,405 Shares of ResMed Inc. $RMD - MarketBeat
Thrivent Financial for Lutherans Acquires 5,212 Shares of ResMed Inc. $RMD - MarketBeat
The Bull Case For ResMed (RMD) Could Change Following FDA-Cleared AI Smart Comfort CPAP Feature - Sahm
Texas Permanent School Fund Corp Sells 5,560 Shares of ResMed Inc. $RMD - MarketBeat
Assenagon Asset Management S.A. Sells 5,635 Shares of ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock beat revenue estimatesPortfolio Performance Report & Intraday High Probability Alerts - ulpravda.ru
Technical Analysis: Will ResMed Inc. stock gain from strong economyTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is ResMed Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Real-Time Volume Analysis - DonanımHaber
Will ResMed Inc. stock deliver better than expected guidanceJuly 2025 Movers & Long Hold Capital Preservation Tips - DonanımHaber
Resmed Inc Officer Plans Sale of Common Stock - MSN
Will ResMed Inc. stock attract more institutional investorsMarket Volume Report & Real-Time Volume Triggers - Улправда
Will ResMed Inc. stock benefit from automationQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Why ResMed Inc. stock is a value investor pickJuly 2025 Short Interest & Smart Money Movement Tracker - Улправда
ResMed Inc. $RMD Shares Acquired by Addenda Capital Inc. - MarketBeat
Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape - Kalkine Media
Is ResMed Inc. stock in correction or buying zoneJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Two Resmed leaders take the J.P. Morgan Healthcare Conference stage - Stock Titan
ResMed (FRA:RMEA) EV-to-OCF : 17.84 (As of Dec. 18, 2025) - GuruFocus
Is It Too Late to Consider ResMed After Weight Loss Drug Concerns and DCF Outlook? - Sahm
Stifel Maintains ResMed (RMD) Hold Recommendation - Nasdaq
Will ResMed Inc. (RME) stock outperform Dow Jones2025 Momentum Check & Community Trade Idea Sharing Platform - Улправда
Stifel Nicolaus Adjusts ResMed Price Target to $260 From $270, Maintains Hold Rating - marketscreener.com
Stifel Lowers Price Target for ResMed (RMD) to $260, Maintains H - GuruFocus
How ResMed Inc. stock performs in easing cyclesJuly 2025 WrapUp & AI Driven Price Predictions - Улправда
Aug Volume: Can ResMed Inc. stock double in next 5 yearsGold Moves & Reliable Intraday Trade Alerts - Улправда
ResMed stock price target lowered to $260 by Stifel on Philips return concerns - Investing.com UK
ResMed Director Acquires Additional Shares in Strategic Move - MSN
ResMed (RMD): Revisiting Valuation After Recent Share Price Pullback - Yahoo Finance
ResMed (NYSE:RMD) Downgraded to "Hold" Rating by Baird R W - MarketBeat
4,600 Shares in ResMed Inc. $RMD Purchased by Sanders Morris Harris LLC - MarketBeat
Tandem upgraded, Zimmer, ResMed downgraded as Baird previews MedTech in 2026 - MSN
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Shorts Report: Will ResMed Inc stock benefit from automationWeekly Profit Analysis & Breakout Confirmation Trade Signals - moha.gov.vn
ResMed (RMD) Downgraded by Baird, Price Target Lowered to $275 | - GuruFocus
Baird Downgrades ResMed to Neutral From Outperform, Adjusts Price Target to $275 From $300 - marketscreener.com
Baird downgrades ResMed stock rating to Neutral on slowing growth By Investing.com - Investing.com Australia
Baird downgrades ResMed stock rating to Neutral on slowing growth - Investing.com
ResMed (RMD): Evaluating the Stock’s Valuation After FDA Clearance for Its AI-Powered Smart Comfort CPAP Feature - Sahm
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors - WebWire
ResMed Inc. $RMD Shares Acquired by Neuberger Berman Group LLC - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):